Walleye Capital’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$763K Buy
3,600
+2,500
+227% +$491K ﹤0.01% 2357
2026
Q1
$216K Sell
1,100
-18,100
-94% -$3.52M ﹤0.01% 3298
2025
Q4
$3.33M Buy
19,200
+8,200
+75% +$1.49M 0.01% 1460
2025
Q3
$2.1M Buy
11,000
+6,200
+129% +$1.1M 0.01% 1538
2025
Q2
$862K Sell
4,800
-6,900
-59% -$1.2M ﹤0.01% 2166
2025
Q1
$1.98M Sell
11,700
-800
-6% -$131K 0.01% 1421
2024
Q4
$1.89M Buy
12,500
+3,900
+45% +$607K ﹤0.01% 1835
2024
Q3
$1.34M Sell
8,600
-14,700
-63% -$2.2M ﹤0.01% 2342
2024
Q2
$3.19M Sell
23,300
-21,800
-48% -$2.99M 0.01% 1673
2024
Q1
$6M Sell
45,100
-7,200
-14% -$934K 0.01% 1167
2023
Q4
$7.21M Buy
52,300
+31,800
+155% +$4.18M 0.02% 865
2023
Q3
$2.5M Buy
20,500
+12,000
+141% +$1.6M 0.01% 1560
2023
Q2
$1.19M Buy
+8,500
New +$1.17M ﹤0.01% 1707
2019
Q4
Sell
-100
Closed -$11K 1890
2019
Q3
$11K Sell
100
-200
-67% -$20.5K ﹤0.01% 1767
2019
Q2
$31K Buy
+300
New +$28.8K ﹤0.01% 1463

Other funds holding DGX

Walleye Capital's DGX Position: Q2 2026 in Review

Walleye Capital reduced its Quest Diagnostics (DGX) stake by 96% in Q2 2026, selling an estimated $418K and leaving 88 shares worth $18.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4400.

Walleye Capital first reported a position in DGX in Q2 2019 and has held it in 12 quarters since. The position peaked at $2.79M in Q4 2025. 1,109 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Walleye Capital held 88 shares of Quest Diagnostics worth $18.7K as of Q2 2026.
  • Walleye Capital sold 2,130 Quest Diagnostics shares in Q2 2026, an estimated $418K.
  • Quest Diagnostics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4400 holding.
  • Walleye Capital first reported a position in Quest Diagnostics in Q2 2019 and has held it in 12 quarters since.
  • Walleye Capital's Quest Diagnostics position peaked at $2.79M in Q4 2025.
  • 1,109 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.